Archives in Cancer Research

  • ISSN: 2254-6081
  • Journal h-index: 11
  • Journal CiteScore: 0.91
  • Journal Impact Factor: 0.6
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
20+ Million Readerbase
Indexed In
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Google Scholar
  • Secret Search Engine Labs
Share This Page

Anti-cancer preparation NSC-631570 (Ukrain) and its efficacy in the treatment of malignant melanoma

World Congress on Immuno Oncology & Clinical Pharmacy
April 18-19, 2019 | Paris, France

Wassil Nowicky and Larysa Skivka

Nowicky Pharma/Ukrainian Anti-Cancer Institute, Austria Taras Shevchenko National University of Kyiv, Ukraine

Keynote: Arch Cancer Res


The first publication on the using NSC-631570 in malignant melanoma describes the full remission in a patient with metastases to the lung. A long lasting remission (more than 10 years without recurrence) has been observed in a patient with malignant nodular melanoma after the treatment with NSC-631570. At the beginning of the NSC631570 therapy liver metastases were present and melanin was excreted with urine. The effects of NSC-631570 alone and in combination with the pathogen associated molecules (PAM) on the cell cycle and apoptotic induction were compared in two melanoma cell lines MM�4 and MM�4M2 with different metastatic properties (cell division rate, hematogenous metastazing, sensitivity to the TNF�induced apoptosis). Apoptosis induction and cell viability were analyzed using trypan blue exclusion test, morphological criteria, DNA gel electrophoresis and flow cytometry. Cell cycle distribution of tumor cells was estimated by flow cytometry. The therapy with NSC- 631570 induced apoptosis in both melanoma cell lines in a dosedependent matter. The cell line with higher metastatic potential was more sensitive to NSC-631570. In the cell line with low metastatic potential, combined use of NSC-631570 and PAM induced apoptosis more effectively

Biography :

Wassil Nowicky, Dipl. Ing., Dr. techn., DDDr. h. c. is the Director of Nowicky Pharma and President of the Ukrainian Anti-Cancer Institute (Vienna, Austria). He is the Inventor of NSC-631570, the anticancer preparation on basis of celandine alkaloids. He is the Author of over 300 scientific articles dedicated to cancer research. He is a real Member of the New York Academy of Sciences, Member of the European Union for Applied Immunology and of the American Association for Scientific Progress, Honorary Doctor of the Yanka Kupala State University of Grodno, doctor Honoris Causa of the Open International University for Complementary Medicine in Colombo, Honorary Member of the Austrian Society on the name of Albert Schweizer. He has received merits of National guild of pharmacists of America award, the Award of Austrian Society of sanitary, hygiene and public health services and others.

E-mail: [email protected]